SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below a widely watched support level have fueled concern about further forced selling and a broader crypto downturn. Traders are divided between calling for more downside and treating the drop as an oversold buying opportunity.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting traders to question the reliability of Microsofts infrastructure and debate whether the disruption could hurt the business. Some speculated about a cyberattack, but that was unconfirmed; others noted the stock held up despite the outage.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial results for GPS in acute myeloid leukemia are expected in November after the trial reached its required event milestone, driving intense focus on the approaching binary readout. Many traders are bullish and speculate about a data leak or short squeeze, while others caution that results remain unknown and the CEOs positive framing is conditional; no successful outcome has been confirmed.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid ongoing FDA discussions and assay refinement. Traders are split between viewing the CMC-related delay as a fixable timing setback that leaves the clinical data intact and criticizing management over execution, disclosure and confidence, with some also concerned about potential dilution.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,724,302,860.16906072. The last known price of Dogecoin is 0.06637358 USD and is down -1.83 over the last 24 hours. It is currently trading on 1545 active market(s) with $637,467,553.75 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins continued decline alongside weakness across the crypto market is driving discussion, with many traders questioning whether it can find a floor and warning of further losses. Others are buying the dip and citing possible technical reversal signals, but no specific confirmed catalyst dominates the conversation.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos quarterly earnings beat and raised outlook, supported by strong networking and AI-infrastructure demand, are driving attention. Traders are split between seeing the results as evidence of a networking growth cycle and questioning why the stocks reaction has been muted, with some also flagging margin pressure and order-book quality.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius shares are under pressure after its strong quarterly results were overshadowed by a lower-end 2026 revenue outlook tied to capacity delays and sharply higher planned capital spending. Bears question execution, financing needs, and the timing of returns, while bulls point to strong AI demand and customer prepayments; Nvidia-related uncertainty is also cited as a headwind.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits pending FDA decision on ivonescimab plus chemotherapy for EGFR-mutated lung cancer is driving a high-stakes, binary-event debate. Bulls point to the drugs clinical data and AstraZenecas investment, while bears focus on the missed statistical-significance threshold for overall survival; speculation that recent price action signals an FDA leak is unconfirmed.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Anthropics confidential IPO filing has renewed attention on Zoom as a potential proxy for the AI company through its investment stake, with traders debating how much of that value is reflected in Zooms shares. A stronger-than-expected quarter and raised full-year outlook add support, though skeptics question whether modest core growth and competition justify the enthusiasm.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs pending decision on Capricors deramiocel application for upper-limb function in Duchenne muscular dystrophy, with traders focused on the November 22 target date and debating whether HOPE-3 data can overcome regulatory concerns and prior advisory-committee criticism. Bulls expect approval and a possible short squeeze, while bears warn of a rejection and sharp downside; the outcome remains uncertain.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Solar farms are built with borrowed money. When yields rise projects get delayed and panel orders get delayed with them. The stocks get sold the same day.

December hike odds went from 77% to 91% in a week. The 10 year yield was 4.86% on Nov 9 when $TOYO closed at 5.42. It&#39;s up to 5.17% after today&#39;s close. The 2 year had its biggest one day jump since April 2025.

$TAN lost 3.7% today. $FSLR lost 3.3% and $ENPH 5.4%. TOYO lost 7.3% which is about twice the sector and how it usually moves on sector days.

The stock had a bad week, the company actually had a good one. The Commerce filing went on the record with the full supply chain documented and short interest came in lower for the third report in a row. Texas panels, a 7 cent a watt federal credit on every one, $240M of signed contracts and cells cleared by Customs are all still there. I bought more on the dip.

Let&#39;s hope Monday is about the company.

Jim Sawicki

Imre Gaburi

Murat Mermer

Sean

newtraderlookingforhope

Pierre Renaud

StockTwits for iOS

TOYO Co., Ltd

Invesco Solar ETF

First Solar Inc

Enphase Energy Inc

Solar farms are built with borrowed money. When yields rise projects get delayed and panel orders get delayed with them. The stocks get sold the same day.

December hike odds went from 77% to 91% in a week. The 10 year yield was 4.86% on Nov 9 when 

 closed at 5.42. It's up to 5.17% after today's close. The 2 year had its biggest one day jump since April 2025.



 5.4%. TOYO lost 7.3% which is about twice the sector and how it usually moves on sector days.

The stock had a bad week, the company actually had a good one. The Commerce filing went on the record with the full supply chain documented and short interest came in lower for the third report in a row. Texas panels, a 7 cent a watt federal credit on every one, $240M of signed contracts and cells cleared by Customs are all still there. I bought more on the dip.

Let's hope Monday is about the company.

ABTrades

YaRight

@ABTrades1 agree, could be some short term
Macro headwinds afffecting the industry but I suspect the Fed reverses course at some point in 2027. I’m a little cautious on the Qtr results. While I suspect they won’t be great because of the revised forward guidance (or lack thereof), I hope to be surprised to the upside. I’m going to wait for earnings before I put more $ at risk, but I am very tempted at these prices.

 agree, could be some short term
Macro headwinds afffecting the industry but I suspect the Fed reverses course at some point in 2027. I’m a little cautious on the Qtr results. While I suspect they won’t be great because of the revised forward guidance (or lack thereof), I hope to be surprised to the upside. I’m going to wait for earnings before I put more $ at risk, but I am very tempted at these prices.